Premium
A 3‐month double‐blind cross‐over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure
Author(s) -
NORDREHAUG J. E.,
OMSJØ I. H.,
VOLLSET S. E.
Publication year - 1992
Publication title -
journal of internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.625
H-Index - 160
eISSN - 1365-2796
pISSN - 0954-6820
DOI - 10.1111/j.1365-2796.1992.tb01244.x
Subject(s) - benazepril , hydrochlorothiazide , medicine , heart failure , diuretic , cardiology , blood pressure , angiotensin converting enzyme , concomitant
. The non‐sulfhydryl selective angiotensin‐converting enzyme inhibitor benazepril (20 mg daily) was compared with hydrochlorothiazide (50 mg daily) in post‐infarction (6–24 months) patients with symptomatic (NYHA functional class 2) mild heart failure. No concomitant drug therapy was given. The study had a double‐blind cross‐over design with 3‐month treatment periods. Both drugs were well tolerated, and both caused a similar reduction in systolic blood pressure. Heart rate was higher with the diuretic. Benazepril improved the NYHA functional class in 17 out of 29 (59%) patients, whereas one patient improved with hydrochlorothiazide ( P = 0.0004). With regard to global efficacy score, benazepril was also superior. Thus, angiotensin‐converting enzyme inhibitors may be superior to diuretics as first‐choice therapy in symptomatic mild heart failure.